In Reply

Journal article

Peer reviewed

Steven E Lipshultz, Stuart R Lipsitz, Stephen E Sallan, Richard D Gelber and Steven D Colan

Journal of clinical oncology, Vol.21(17), pp.3377-3378

2003-09-01

Metrics

5 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.219 Cancer Drugs; 1.219.1342 Cardiotoxicity
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: In Reply
Creators: Steven E Lipshultz - University of Rochester Medical Center, Golisano Children’s Hospital at Strong, and University of Rochester School of Medicine and Dentistry, Rochester, NY
Stuart R Lipsitz - Medical University of South Carolina, Charleston, SC
Stephen E Sallan - Dana-Farber Cancer Institute, Children’s Hospital, Harvard School of Public Health, and Harvard Medical School, Boston, Massachusetts
Richard D Gelber - Dana-Farber Cancer Institute, Children’s Hospital, Harvard School of Public Health, and Harvard Medical School, Boston, Massachusetts
Steven D Colan - Dana-Farber Cancer Institute, Children’s Hospital, Harvard School of Public Health, and Harvard Medical School, Boston, Massachusetts
Publication Details: Journal of clinical oncology, Vol.21(17), pp.3377-3378
Academic Unit: UMMG Department of Pediatrics
Language: English
Resource Type: Journal article
Record Identifier: 991031614570802976